The Vienna Prograf and Endothelial Progenitor Cell Extension Study
Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
Conversion of renal transplant recipients from either tacrolimus or cyclosporin A to
tacrolimus modified release to investigate the effects of the MDR1/CYP450 genotype on the
trough blood levels of tacrolimus with modified galenic (tacrolimus MR4; Advagraf®).